Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Smartphone donations

The Diabetes Research Team is requesting donations of old iPhones for a new study investigating the effect of real time CGM on every day diabetes management.

News & Events

Diabete$ Re$earch in Au$tralia

It may surprise you to know that the Australian government has invested almost $300 million dollars since 2000 towards research and clinical trials for diabetes

News & Events

Low Carbohydrate Diets

Carbohydrate restriction is used by some individuals with type 1 diabetes to reduce glucose excursions after eating a meal.

News & Events

Recruitment for AdDIT now complete

Young people diagnosed with Type 1 Diabetes are at risk of complications from their diabetes including kidney, heart, eye and vascular disease.

News & Events

WA teenager with type 1 diabetes on a mission to become a pro-cyclist

A wiry tall teenager, who was struggling somewhat with his blood glucose control, he turned up on his trusty bike, and we had something in common to talk about.

A community-led, trauma-informed psychosocial intervention to improve health outcomes of children and young people with Type-1 diabetes

T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.

Research

Stillbirth in Iceland 1996–2021: Incidence and etiology

This study describes the stillbirth rate in Iceland 1996-2021 and the causes of stillbirth according to the Stockholm classification of stillbirth, comparing time periods and gestational age groups.

Research

Leukaemia

Leukaemia, also spelled leukemia, is a cancer that develops in the bone marrow and results in abnormal white blood cells. It is the most common cancer in children, accounting for almost a third of all childhood & teen cancers.

Research

Pertussis

Pertussis, also known as whooping cough, is a highly contagious respiratory disease.

Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.